Design, Synthesis, Molecular Docking Studies and in Silico Prediction of ADME Properties of New 5-Nitrobenzimidazole/thiopyrimidine Hybrids as Anti-angiogenic Agents Targeting Hepatocellular Carcinoma | ||
| Egyptian Journal of Chemistry | ||
| Volume 67, Issue 1, January 2024, Pages 437-446 PDF (867.19 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejchem.2023.212212.7998 | ||
| Authors | ||
| Heba Abdelmohsen* 1; Ahmed M El Kerdawy2 | ||
| 1Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Giza 12622, Egypt | ||
| 2Lecturer in the pharmaceutical and medicinal chemistry department, Faculty of Pharmacy Cairo University | ||
| Abstract | ||
| In the current study, a new series of 5-nitrobenzimidazole-pyrimidine hybrids 12a,b, 13 and 14a-c were designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. The designed and synthesized conjugates demonstrated a moderate to potent inhibitory activity on VEGFR-2 with IC50 reaching 2.83 µM. Moreover, they demonstrated a moderate to potent cytotoxic activity on HepG2 cell line. Compound 14c was the most potent hybrid with IC50 of 2.83 µM on VEGFR-2 and IC50 of 4.37 µM on HepG2 cell line. In silico docking of the synthesized hybrids 12a,b, 13 and 14a-c in the VEGFR-2 binding pocket proved their capability to perform the important interactions required for VEGFR-2 inhibition at its binding site. In addition, the synthesized molecules proved promising predicted ADME properties to be further optimized for the discovery of new targeted anticancer agents. | ||
| Keywords | ||
| 5-Nitrobenzimidazole-thiopyrimidine; VEGFR-2; hepatocellular carcinoma; ADME | ||
|
Statistics Article View: 659 PDF Download: 542 |
||
